AGEN Agenus Inc

-

Agenus Missed Consensus Estimates

Friday, August 7, 2026 · 12:00 AM ET

Agenus (AGEN) reported a loss of $0.01 per share on revenue of $34.52 million for the second quarter ended June 2026. The consensus earnings estimate was $0.05 per share on revenue of $34.00 million. The company missed consensus estimates by 120.00% while revenue grew 34.31% on a year-over-year basis.

Agenus Inc along with its subsidiaries is a biopharmaceutical company. The Company is engaged in developing and commercializing technologies to treat cancers and degenerative disorders.

Earnings Whisper Grade
Power Rating
Reported Earnings
($0.01)
Earnings Whisper®
Consensus Estimate
$0.05
Earnings Surprise
Earnings Growth99.0 %
Reported Revenue
$34.52M
Revenue Estimate
$34.00M
Revenue Surprise
Revenue Growth34.3 %